U.S. Biomaterials Corp. of Timonium, Md., and Biomatrix Inc.(NASDAQ:BIOX) of Ridgefield, N.J., announced that they haveentered into a collaborative agreement to develop and marketbiomaterials and biomaterial products for use in the treatmentof specific therapeutic indications.
The products will be produced by combining Biomatrix'sproprietary hylan or other hyaluronan derivatives with U.S.Biomaterials' Bioglass or other bioactive ceramics, which form adirect chemical bond with tissues when implanted into thebody. Hylan is the generic name for certain chemicallymodified forms of hyaluronan, a polysaccharide present in theintercellular matrix of nearly all connective tissues.
(c) 1997 American Health Consultants. All rights reserved.